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S Mårild9, L Iacoviello10 and W Ahrens1,11 on behalf of the IDEFICS consortium
OBJECTIVES: C-reactive protein (CRP) is involved in a wide range of diseases. It is a powerful marker for inﬂammatory processes
used for diagnostic and monitoring purposes. We aimed to establish reference values as data on the distribution of serum CRP
levels in young European children are scarce.
SUBJECTS: Reference values of high-sensitivity CRP concentrations were calculated for 9855 children aged 2.0–10.9 years, stratiﬁed
by age and sex. The children were recruited during the population-based European IDEFICS study (Identiﬁcation and prevention of
Dietary- and lifestyle-induced health Effects in Children and infantS) with 18 745 participants recruited from 2007 to 2010.
RESULTS: In 44.1 % of the children, CRP values were below or equal the detection limit of 0.2 mg/l. Median CRP concentrations
showed a slight negative age trend in boys and girls, whereas serum CRP values were slightly higher in girls than in boys across all
age groups.
CONCLUSIONS: Our population-based reference values of CRP may guide paediatric practice as elevated values may require
further investigation or treatment. Therefore, the presented reference values represent a basis for clinical evaluation and for future
research on risk assessment of diseases associated with increased CRP levels among children.
International Journal of Obesity (2014) 38, S26–S31; doi:10.1038/ijo.2014.132
INTRODUCTION
C-reactive protein (CRP) is an acute-phase protein of the pentraxin
family produced in the liver in response to inﬂammatory signals,
particularly interleukin-6, which is synergistically enhanced by
IL-1β. It is released during infection, systemic inﬂammation and
tissue damage and activates the classical complement pathway.
CRP binds to phosphocholine and related molecules on micro-
organisms and on membranes of apoptotic and necrotic cells. Its
binding to phosphocholine improves opsonisation and phagocy-
tosis by macrophages. In addition, CRP binds to certain Fc-gamma
receptors on the surface of leukocytes, which also lead to the
stimulation of phagocytosis and the release of cytokines.1
In healthy subjects, the average serum CRP concentration is
o1mg l− 1.2 However, the CRP concentration rises quickly up to
1000mg l− 1 in the ﬁrst few days following an acute-phase
stimulus and decreases back to baseline with a half-life of 19 h
when the stimulus has ceased.3
Slightly elevated levels of CRP are related to overweight and
obesity in children and adults.4 Elevation of CRP in obesity results
from inﬁltration of the expanded adipose tissue by macrophages
that release inﬂammatory signals and cytokines such as inter-
leukin-6, the main stimulus for CRP production.5
Moreover, slightly elevated CRP is an independent predictor
of coronary events and stroke and has been associated with
cardiovascular mortality and all-cause mortality in adults.6
An association between elevated CRP and markers for
cardiovascular risk was reported in children as well.7–10 In addition,
increased CRP has been associated with cancer11,12 and has shown
to be a prognostic marker in various malignancies in adults,13–15
whereas data in children are scarce. Furthermore, elevated CRP
levels are associated with an increased risk of type 2 diabetes in
adults16 and are correlated with insulin resistance in children.17 As
serum CRP concentration reﬂects the magnitude of inﬂammation,
it has also become a routine laboratory parameter in daily clinical
practice for diagnosis and monitoring of autoimmune inﬂamma-
tory disorders such as rheumatoid arthritis.18,19 To render CRP a
useful marker in children, age-speciﬁc reference values are needed.
Although CRP reference percentiles of a large US cohort of
children have been reported,20 there are only few population-
based studies on paediatric CRP reference values in Europe. Most
previous studies were restricted to a small number of subjects
from healthy or hospital-based populations and only few nation-
wide or large-scale population studies reported CRP values.21–23
Therefore, the aim of this study was to establish reference values
for prepubertal children in Europe.
SUBJECTS AND METHODS
Study subjects
A cohort of 16 228 children aged 2.0–8.9 years was examined in a
population-based baseline survey (T0) in eight European countries ranging
from North to South and from East to West (Sweden, Germany, Hungary,
Italy, Cyprus, Spain, Belgium and Estonia) from autumn 2007 to spring
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2008.24 Additional 2517 children aged 2.0–10.9 years were newly recruited
during a second survey (T1) 2 years later to add up to the study sample of
the present analysis (n= 18 745).
Examinations and CRP analysis
The examination programme included standard anthropometric measures
such as body weight and height, a personal interview on health conditions
and the collection of blood for analysis, reported in detail elsewhere.24,25 In
addition, a detailed description of blood processing, shipment, storage and
quality management during the baseline survey has been published
earlier.26,27 The same procedures were applied during the second survey.
The examinations were suspended during the summer holidays. As the
fasting status was important for other blood marker analyses (for example,
blood lipids) with regard to IDEFICS main topic on lifestyle and dietary
behaviour in children, blood samples were collected mainly in the morning
(83% before 10 a.m., 95% before 11 a.m.) and stored in the order of
appearance at the study site. The blood samples were analysed directly
after shipment from each country to a central laboratory according to a
predeﬁned shipment schedule. IDEFICS samples were randomly integrated
in the normal routine samples of the lab. CRP levels were measured with
latex-enhanced nephelometry (BN2-Nephelometer, Siemens, Eschborn,
Germany) with a lower detection limit of 0.2 mg/l. The CRP measurements
were performed under the legally regulated quality management system
RiliBÄK that includes internal and external control samples on different
levels. The RiliBÄK system does not allow the release of samples without
valid quality control and includes a system to check for drifts. External
quality control certiﬁcates are published on the laboratory website (www.
labmed.de).
Inclusion and exclusion criteria for the reference population
Of the 18 745 participants aged 2.0–10.9 years, serum concentrations of
CRP were analysed from all 11 641 children who provided a blood sample.
Deﬁning the reference population, our aim was to present CRP values for a
large European population of children. Serum levels of CRP ⩾ 10mg l− 1 are
generally believed to be attributed to infection or inﬂammation in adults.28
Therefore, we used this cut-off to exclude 274 children with pathologically
elevated CRP levels. Furthermore, the body mass index was determined as
obesity is associated with inﬂammatory processes as well.4 The parents
were asked: ‘Has the child taken any kind of medication within the last
24 h?’ For every child who had taken medication, that is, prescription drugs
or over-the-counter drugs within the last 24 h before blood collection we
assumed a poor health status and excluded them all, regardless of
indication. Thus, 1786 children were excluded from the analysis group
because of pathologically elevated CRP levels (n=274), obesity classiﬁed
according to Cole and Lobstein29 (n=773) or current medication (n=882),
leaving 9855 children aged 2.0–10.9 years in the analysis group (Figure 1).
Unfortunately, the categories on the checklist of diseases queried during
the medical interview did not allow the identiﬁcation of pathophysio-
logical conditions that were related to inﬂammation and hence may have
inﬂuenced CRP levels. But we performed sensitivity analyses to assess the
impact of varying inclusion criteria on the serum levels of CRP.
Statistical analyses
To calculate percentile curves, we used the General Additive Model for
Location Scale and Shape that was developed by Rigby and
Stasinopoulos.30 This method is an extension of the LMS method to
model the distribution of CRP depending on multiple covariates while
accounting for dispersion, skewness and particularly the kurtosis of this
distribution.30,31
We calculated percentile curves of CRP as a function of the covariate
age, stratiﬁed by sex, using the General Additive Model for Location Scale
and Shape method. The General Additive Model for Location Scale and
Shape method is an extension of the LMS method that models three
parameters depending on one explanatory variable: M accounts for the
median of the outcome variable and the coefﬁcient of variation (S)
accounts for the variation around the mean and adjusts for non-uniform
dispersion, whereas the skewness (L) accounts for the deviation from a
normal distribution using a Box–Cox transformation. We used the gamlss
package (version 4.2–6) of the statistical software R (version 3.0.1).32
Different distributions, that is, the Box–Cox transformation, gamma and
inverse Gaussian distribution were ﬁtted to the observed distribution
of CRP. Moreover, the inﬂuence of age on parameters of the considered
distributions was modelled either as a constant, as a linear function or as a
cubic spline of the covariate. Goodness of ﬁt was assessed by the Bayesian
Information Criterion and Q–Q plots to select the ﬁnal model including the
ﬁtted distribution of CRP and the inﬂuence of the covariate on distribution
parameters. The CRP serum values were measured with a detection limit of
0.2 mg l− 1 and a precision of 0.1 mg l− 1 (for example, values ⩽ 2.4 mg l− 1
rounded to 0.2 mg l− 1). As 44.1 % of CRP blood values of the reference
population were below or equal to the detection limit the distribution of
CRP was strongly skewed and distributions available in the gamlss package
could not accurately be ﬁtted regarding the correct percentage of cases
below the percentile curves. Hence, CRP observations equal to 0.2 mg l− 1
were repeatedly randomised within [0, 0.24] based on the uniform
distribution to identify the best ﬁtted model. The ﬁnal model for boys and
girls is based on a Box–Cox transformation distribution where the
distribution parameters were modelled as follows: the location parameter
μ linearly, the scale parameter log(σ) and the shape parameters ν and log(τ)
as constants. CRP observations equal to 0.2 mg l− 1 were again uniformly
randomised within (0, 0.24) for 100 replications to eventually calculate
mean percentile curves in the ﬁnal analysis. With 44.1 % of serum CRP
values below or equal the detection limit only the 50th, 75th, 90th, 95th,
97th, 97.5th and 99th CRP percentiles were calculated.31,32
RESULTS
The characteristics of the reference population are summarised in
Table 1. Our analysis group did not differ substantially from the
whole study population (see Ahrens et al.33 on prevalence of
overweight; this issue). Median CRP levels ranged from 0.2 to
0.3 mg l− 1 in all countries, except for Italy where median CRP
levels were higher (0.5 mg l− 1).
Serum CRP concentrations ranged from 0.2 to 9.7 mg l− 1 in
boys and from 0.2 to 9.8 mg l− 1 in girls (min to max). Almost half
of the children (44.1 %) had CRP values lower or equal to the
detection limit of 0.2 mg l− 1. Age- and sex-speciﬁc 50th, 75th,
90th, 97th and 99th CRP percentiles of the reference population of
2.0–10.9-year-old children are presented in Figure 2 and in Table 2
(95th and 97.5th CRP percentiles in Supplementary Figure A;
Supplementary Table A). Median CRP concentrations showed a
slightly negative age trend, both, in boys and girls. Upper
percentiles displayed higher CRP values in younger children.
CRP percentiles were generally higher in girls than in boys of the
same age.
Sensitivity analyses were performed to conﬁrm the robustness
of our data. The inﬂuence of obesity on CRP levels was conﬁrmed
by excluding obese children as shown in Supplementary Figure B.
Multiple deﬁnitions of obesity were applied according to the
International Obesity Task Force as published by Cole and
Lobstein,29 the Centers for Disease Control and Prevention
(CDC)34 and the World Health Organisation (WHO).35,36 This
sensitivity analysis showed that the 75th, 90th and 95th CRP
percentiles from non-obese children were lower, in particular for
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Figure 1. Selection of the reference population.
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children from the analysis. Moreover, an inﬂuence of medication
was apparent, especially in younger children, with higher CRP
levels in children having taken medication (Supplementary
Figure C). An additional sensitivity analysis revealed that there
were negligible differences in CRP levels when children with any
kind of reported current disease or elevated blood pressure were
excluded (Supplementary Figure D).
DISCUSSION
Age
In adults, CRP concentrations are often assumed to be indepen-
dent of age. Children have lower CRP levels than adults, which are
assumed to increase with age to reach adulthood levels. There-
fore, we generated age-speciﬁc CRP percentiles to serve as
reference values for children. Surprisingly, we observed a slight
negative trend of median CRP concentrations with age in both,
boys and girls. This slight negative trend is driven by the upper
percentiles, which showed a marked negative trend until the age
of 11. In a large German cohort study, the mean CRP level was
quite stable for 2–11-year-old children, but increased in adoles-
cent girls 413 years old.37 In North American children from the
NHANES study, the geometric mean of CRP barely increased
between the age of 3 and 14 years, but was rising in females from
the age of 15 years onwards.20 Cook et al.8 found a stronger rise in
CRP levels by 15 % between the age of 10 and 11 years in British
children calculating the proportional change in CRP for a 1 s.d.
increase. Overall, available data indicate that average CRP values
change only marginally in younger children, whereas they seem to
rise during adolescence. It is still an open question to what extent
maturational stage or increasing use of oral contraceptives or
smoking behaviour might be associated with elevated CRP
levels.37
The strong negative trend of the upper percentiles observed in
our data is conﬁrmed by the ﬁndings of Soldin et al.38 In children
aged 13 months to 14 years, the 97.5th percentiles were highest in
the youngest groups. Young children often suffer from infections
as they start to get in contact with other children in
kindergartens.39–41 Higher CRP values in the upper percentiles in
younger age groups might thus represent beginning or fading
subclinical infections that are more likely in these age groups.
Sex
In line with several other studies,8,20,37,38 we found CRP to be
higher in girls than in boys. On the contrary, two other studies
reported no sex differences in children.21,42 Both reported only
CRP reference intervals (2.5th and 97.5th percentile) for broad age
groups and did not investigate sex differences more closely in
between. Surprisingly, in male participants of an adolescent study
population even higher CRP concentrations were measured than
in female participants.23
Table 1. Basic characteristics of the reference population for boys and
girls
Girls Boys
N (%) N (%)
Sex 4854 (49.3) 5001 (50.7)
Mean (s.d.) Mean (s.d.)
Age, years 6.53 (1.91) 6.45 (1.91)
Weight, kg 23.40 (6.52) 23.76 (6.67)
Height, cm 119.8 (13.2) 120.5 (13.2)
BMI, kgm−2 16.00 (1.84) 16.05 (1.78)
BMI, z-score 0.15 (0.99) 0.11 (1.00)
N (%) N (%)
Age categories
2–2.9-year olds 99 (2.0) 101 (2.0)
3–3.9-year olds 478 (9.9) 531 (10.6)
4–4.9-year olds 639 (13.2) 689 (13.8)
5–5.9-year olds 592 (12.2) 645 (12.9)
6–6.9-year olds 757 (15.6) 766 (15.3)
7–7.9-year olds 1067 (22.0) 1055 (21.1)
8–8.9-year olds 796 (16.4) 794 (15.9)
9–9.9-year olds 288 (5.9) 297 (5.9)
10–10.9-year olds 138 (2.8) 123 (2.5)
BMI categories
Thinness grade I–III 592 (12.2) 617 (12.3)
Normal weight 3557 (73.3) 3766 (75.3)
Overweight 705 (14.5) 618 (12.4)
Survey
T0 4351 (89.6) 4546 (90.9)
T1 503 (10.4) 455 (9.1)
Abbreviations: BMI, body mass index; %, sex-speciﬁc percentage of
corresponding categories.






































Figure 2. Age- and sex-speciﬁc CRP percentiles of the reference population. Pn indicates the nth percentile.
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CRP concentration
Median CRP concentrations in our 2.0–10.9-year-old children were
low, close to the detection limit of high-sensitive assays. Previously
reported median CRP values were similar to our data and ranged
from 0.21 mg l− 1 in 5–13-year-old boys22 to 0.3 mg l− 1 in 3–9-
year-old children20 and up to 0.33 and 0.54 mg l− 1 in 11–13-year-
old girls and boys, respectively.43 A comparison of median CRP
concentrations between studies is difﬁcult as values depend on
detection limits and are often reported for different age groups.
Our 95th percentiles ranged from 1.8 to 4.1 mg l− 1 for 2.0–10.9-
year-old boys and girls. This range is similar to the one reported by
the large North American cohort study NHANES. In children,
3–9 years of age, the 95th percentile was 3.4 mg l− 1 if CRP
concentrations 410mg l− 1 were excluded.20 In a French study,
the 95th percentiles of apparently healthy children with CRP
o20mg l− 1 were lower, with 1.45 mg l− 1 in 5–13-year-old boys
and 1.9 mg l− 1 in 5–18-year-old girls,22 although the inclusion
criteria regarding elevated CRP levels were less strict than ours. As
we measured the highest CRP levels in the youngest children, the
lower 95th percentile in the French study population is probably
due to the older age range.
Reporting of the 97.5th instead of the 95th percentiles probably
explain the higher concentrations that were observed in 4–10-
year-old children recruited regardless of their health status in a
study by Soldin et al.38 In those children, the 97.5th percentiles
varied from 7.9 mg l− 1 in boys to 10.0 mg l− 1 in girls, whereas our
97.5th percentiles ranged from 2.8 to 6.3 mg l− 1 in 2.0–10.9-year-
old boys and girls. The highest 97.5th percentile of 11.3 mg l− 1
CRP was reported in a Swedish study with children between the
age of 6 months and 18 years although children with chronic
diseases or infections were excluded.21 On the contrary, the lowest
97.5th CRP percentiles of 1 mg l− 1 for boys and girls were
reported from a Canadian study.42 We can only speculate whether
the removal of outliers or the exclusion criteria had an impact on
these reference values, as it was not clearly stated how many
outliers had been removed and how the information regarding
the health status was obtained. Taken together, differences in
published upper percentiles mainly arise because studies report
different percentiles and apply different exclusion criteria.
Inﬂammation
The increase of CRP in the pathophysiology of inﬂammation was
the reason for the exclusion criteria in the present study in order
to remove the inﬂuence of inﬂammatory processes in children
with pathologically elevated CRP levels ⩾ 10mg l− 1, obesity and
medication. Any of the applied exclusion criteria indicating poor
health led to lower CRP concentrations for each percentile in the
reference population. By excluding all children who have taken
any kind of medication, many children were excluded whose
serum CRP concentrations have not been altered. As these
children could be considered similar to those in the reference
population the data were not biased by this exclusion.
The questionnaire was not sufﬁciently speciﬁc for the differ-
entiation of diseases and their underlying inﬂammatory patho-
physiologies. We did not exclude children with current diseases
since a sensitivity analysis showed negligible differences in CRP
levels when children reporting current diseases were excluded.
We assume that the proportion of children with inﬂammatory
conditions was only small.
Obesity
A cross-sectional and longitudinal analysis relating CRP to
overweight/obesity and cardiometabolic risk factors in European
children of the IDEFICS project was recently published.7 In
agreement with numerous other studies, high CRP concentrations
were positively associated with adiposity in children and
adolescents as recently reviewed by Choi et al.4 A sensitivity
analysis conﬁrmed the effect of obesity on CRP levels in our study
population as well.
It is a major strength of our data that they are based on a large
heterogeneous population. Therefore, it was decided for the
reference values to not discriminate between countries. Actually,
CRP levels were quite comparable between countries. Only in
Italian children the median CRP levels were elevated, probably
caused by the extremely high prevalence of overweight and
obesity in this country.44
As blood samples in IDEFICS were collected mainly in the
morning our data are not appropriate to address a possible
inﬂuence of the time of day of sampling on serum CRP levels.
Table 2. Percentiles of hs-CRP (mg l− 1) calculated with GAMLSS
Age (years) Percentiles for girls Age (years) Percentiles for boys
50 75 90 97 99 50 75 90 97 99
2–o2.5 0.5 1.2 2.5 5.5 10.2 2–o2.5 0.4 1.0 2.2 5.3 10.7
2.5–o3 0.5 1.1 2.5 5.4 9.9 2.5–o3 0.4 0.9 2.1 5.1 10.4
3–o3.5 0.5 1.1 2.4 5.3 9.7 3–o3.5 0.4 0.9 2.1 4.9 10.1
3.5–o4 0.5 1.1 2.4 5.1 9.5 3.5–o4 0.3 0.9 2.0 4.8 9.8
4–o4.5 0.4 1.1 2.3 5.0 9.2 4–o4.5 0.3 0.8 1.9 4.6 9.5
4.5–o5 0.4 1.0 2.2 4.9 9.0 4.5–o5 0.3 0.8 1.9 4.5 9.2
5–o5.5 0.4 1.0 2.2 4.8 8.8 5–o5.5 0.3 0.8 1.8 4.3 8.8
5.5–o6 0.4 1.0 2.1 4.6 8.6 5.5–o6 0.3 0.8 1.7 4.2 8.5
6–o6.5 0.4 1.0 2.1 4.5 8.3 6–o6.5 0.3 0.7 1.7 4.0 8.2
6.5–o7 0.4 0.9 2.0 4.4 8.1 6.5–o7 0.3 0.7 1.6 3.9 7.9
7–o7.5 0.4 0.9 2.0 4.3 7.9 7–o7.5 0.3 0.7 1.5 3.7 7.6
7.5–o8 0.4 0.9 1.9 4.2 7.6 7.5–o8 0.3 0.6 1.5 3.5 7.3
8–o8.5 0.4 0.9 1.8 4.0 7.4 8–o8.5 0.2 0.6 1.4 3.4 6.9
8.5–o9 0.3 0.8 1.8 3.9 7.2 8.5–o9 0.2 0.6 1.4 3.2 6.6
9–o9.5 0.3 0.8 1.7 3.8 7.0 9–o9.5 0.2 0.6 1.3 3.1 6.3
9.5–o10 0.3 0.8 1.7 3.7 6.7 9.5–o10 0.2 0.5 1.2 2.9 6.0
10–o10.5 0.3 0.7 1.6 3.5 6.5 10–o10.5 0.2 0.5 1.2 2.8 5.7
10.5–o11 0.3 0.7 1.6 3.4 6.3 10.5–o11 0.2 0.5 1.1 2.6 5.3
Abbreviations: GAMLSS, General Additive Model for Location Scale and Shape; hs-CRP, high-sensitivity C-reactive protein.
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Moreover, there are very few hints in the literature on a possible
role of time of day of sampling as a covariate for CRP, but also few
data against it. Diurnal variation of CRP is not commonly regarded
as an inﬂuence and our data cannot contribute to this issue.
No seasonal variations of CRP levels were observed in our data.
This conﬁrms a previous study that was especially designed to
examine seasonal changes in cardiovascular risk biomarkers and
that did not report seasonal variation of CRP levels.45
Besides the inﬂuence of age, sex and obesity, serum CRP
concentrations underlie substantial intra-individual variability.46
Thus, the Centers for Disease Control and Prevention and the
American Heart Association recommend to assess the mean of at
least two measurements, taken 2 weeks apart, for evaluation
of a person's true CRP status. Elevated CRP concentrations
(⩾10mg l− 1) without obvious signs of disease are usually due to
an asymptomatic inﬂammatory response or subclinical infection.
In this case, the measurement should be repeated.28 Moreover, in
the case of recurrent CRP elevations below 10mg l− 1, the
underlying cause should be further investigated.
CONCLUSION
Reference percentiles of CRP have an important role in clinical
practice for diagnosis and monitoring of inﬂammatory diseases.
The present study is the ﬁrst to provide pan-European age-speciﬁc
reference values of CRP for children that may guide paediatric
practice and provide a basis for future clinical and epidemiological
research on inﬂammation-related disorders in children.
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